IntraLase developed a revolutionary all-laser surgical technology that made precise surgical flaps for laser vision correction procedures that has seen enormous success in the field of refractive surgery. IntraLase had an initial public offering in 2004 and was acquired by Advanced Medical Optics in 2007. Advanced Medial Optics was acquired by Abbott Labs in 2009.
IVT was founded in 1983 to develop new technologies and devices for use in the field of intravascular intervention in arteriosclerotic disease. The company introduced tools for use in vascular microsurgery as well as in traditional balloon dilatation intervention. The company was acquired by Boston Scientific in 2001.
Innovasive Devices made and sold sports medicine devices used in the surgical repair of soft tissue in the knees and shoulders. It was acquired by Johnson & Johnson in 1999.
Epicor Medical was founded in 1999 to develop new devices and procedures for the treatment of atrial fibrillation using high-intensity focused ultrasound. Epicor Medical's innovative approach to treating atrial fibrillation stands to cure patients, while minimizing complications associated with most invasive treatments available today. St. Jude Medical acquired the company in 2004.
ArthroCare develops and manufactures surgical devices, instruments, and implants that enhance surgical techniques and improve patient outcomes. Many of ArthroCare’s devices use its patented Coblation technology, which precisely dissolves target tissue and limits damage to surrounding healthy tissue.
Signal was established to develop a new generation of small molecule pharmaceuticals based on recent discoveries about the way genes are regulated. The company's products used gene control — essentially turning genes on and off — to treat inflammatory diseases, viral infections, and neurobiological disorders. The company was acquired by Celgene in September 2000.
Salmedix was a start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon in May 2005.
NovaCardia was a pharmaceutical company focused on developing and commercializing a portfolio of novel small molecule drugs for cardiovascular care. NovaCardia was acquired by Merck in 2007.
Myogen, a University of Colorado Medical Center-based company, developed therapeutics for the treatment of heart disease. The company's strategy was to leverage its molecular and clinical expertise in heart muscle disease to discover new therapeutic targets for drug development, and develop and add value to in-licensed products. Myogen had an initial public offering in 2003, then was acquired by Gilead Pharmaceuticals in 2006.
Inspire Pharmaceuticals discovered and developed breakthrough products to treat diseases involving impaired hydration of the body's mucosal surfaces such as chronic bronchitis and dry eye disease. The products were targeted at disorders with high unmet medical needs representing large, near-term market opportunities. Inspire had an initial public offering in 2000 and was acquired by Merck in 2011.